全文获取类型
收费全文 | 79篇 |
免费 | 4篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 5篇 |
妇产科学 | 4篇 |
基础医学 | 6篇 |
口腔科学 | 4篇 |
临床医学 | 7篇 |
内科学 | 13篇 |
神经病学 | 6篇 |
外科学 | 20篇 |
综合类 | 2篇 |
预防医学 | 3篇 |
药学 | 3篇 |
肿瘤学 | 9篇 |
出版年
2021年 | 1篇 |
2020年 | 1篇 |
2018年 | 1篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2014年 | 4篇 |
2013年 | 1篇 |
2012年 | 3篇 |
2011年 | 2篇 |
2010年 | 2篇 |
2009年 | 1篇 |
2008年 | 6篇 |
2007年 | 8篇 |
2006年 | 3篇 |
2005年 | 7篇 |
2004年 | 8篇 |
2003年 | 3篇 |
2002年 | 6篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1989年 | 2篇 |
1987年 | 2篇 |
1985年 | 2篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1975年 | 1篇 |
1970年 | 1篇 |
1946年 | 1篇 |
1944年 | 1篇 |
排序方式: 共有84条查询结果,搜索用时 15 毫秒
1.
McCuddin CR Miike LH Pangelinan V Franco RW 《Asian American and Pacific Islander journal of health》1994,2(3):213-253
PURPOSE OF THE PAPER. The purposes of this report were to identify Pacific American health care priorities, recommend how these needs can be addressed in national health care reform legislation, and inform national leaders of the cultural and social context withing which these needs must be met. SUMMARY OF METHODS UTILIZED. In concert with a team of researchers, the authors compiled and analyzed extant literature on the health care of Pacific Americans; discussions were held with health care professionals, state and territorial health care leaders, and agencies and organizations with substantial experience and expertise in health care promotion and development; a two-day health symposium was conducted by Pacific American health care community leaders to review the initial findings, conclusions, and recommendations of the draft report; and follow up meetings were heald with actual communitiy health care providers to validate the data and recommendations of the report. PRINCIPAL FINDINGS. Pacific Americans have collective historical and political relationship not only with the federal government and the continental United States, but also to each other's island state or territory. Thus, common needs and unique interrelationships serve to highlight the importance of the differences between western-oriented and Pacific American health care providers. There is a profound lack of health resources in many Pacific American communities, and even when health resources are potentially available, poor access to health care compounds the need. Pacific Americans are a mobile people with large numbers residing in California, Oregon, Washington, Nevada, Texas, Utah, and the New York-Virginia corridor. Their health needs continue even when they do not reside in their home bases. CONCLUSIONS. Pacific Americans know best how to bridge the cultural gap that continues to exist between them and western-oriented health care providers; improvements in their health care is best accomplished by Pacific Americans themselves. Pacific American health care did not start from an "Even playing field"; hence, the mismatch in resources and needs is so pronounced that it argues not only for continued but also greatly expanded federal support for enabling services, research development, and professional education and development. The federal government must collect and develop better demographic and health access information specifically and separately for Pacific Americans. Baseline data for Pacific American populations, regardless of their residence, must be available and analyzable in terms of community and/or geographic areas. Only then can effective programs be established, managed, evaluated, and improved. KEY WORDS. American Samoans; Chamorrors; Hawaiians; Pacific Americans; Pacific Islanders&semi. 相似文献
2.
Alejandro Sousa Brant A. Inman Idelfonso Piñeiro Victor Monserrat Alberto Pérez Vincente Aparici 《International journal of hyperthermia》2014,30(3):166-170
Purpose: Ths paper reports a pilot/feasibility trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) prior to transurethral resection of bladder tumour (TURBT) for non-muscle invasive bladder cancer (NMIBC). Materials and methods: A pilot/feasibility clinical trial was performed and 15 patients with intermediate to high-risk NMIBC received HIVEC prior to TURBT. HIVEC consisting of eight weekly instillations of intravesical MMC (80?mg in 50?mL) delivered with the novel Combat BRS® system at a temperature of 43?°C for 60?min. Treatment-related adverse effects were measured and patients were followed for 2 years for disease recurrence. Results: A total of 119 HIVEC treatments occurred. Grade 1 adverse events consisted of irritative bladder symptoms (33%), bladder spasms (27%), pain (27%), haematuria (20%) and urinary tract infection (UTI; 14%). Grade 2 adverse events were bladder calcification (7%) and reduced bladder capacity (7%). No grade 3 or higher toxicity was observed. At TURBT, eight patients (53%) were complete responders (pT0) while seven (47%) were partial responders. With a median follow-up of 29 months, the 3-year cumulative incidence of recurrence was 15%. Conclusions: The Combat BRS® system achieved target bladder temperatures and delivered HIVEC with a favourable side-effect profile. Our pilot trial also provides preliminary evidence of treatment efficacy. 相似文献
3.
Bruno R Sacchi P Puoti M Soriano V Filice G 《The American journal of gastroenterology》2002,97(7):1598-1606
HIV-hepatitis C virus (HCV) coinfection is common and affects more than one-third of all HIV infected persons worldwide. Prevalence among risk categories varies according to shared risk factors for transmission, mainly intravenous drug use (IDU) and hemophiliacs. Chronic HCV infection seems to accelerate the course of HIV disease, resulting in a worsened clinical and immunological progression. At the same time, several studies suggest that HIV disease modifies the natural history of HCV infection, leading to a faster course of progression from active hepatitis to cirrhosis, to end stage liver disease and death. HCV infection mimics opportunistic diseases because its natural history is significantly accelerated in HIV patients. Since highly active antiretroviral therapy (HAART) has slowed the progression of HIV disease and decreased the rate of HIV associated mortality, the prognosis of HIV disease has been modified, and the need to treat HCV coinfection become a significant issue. Because of the poor response rate obtained by either interferon alone or interferon thrice weekly plus ribavirin, the combination of pegylated interferon and ribavirin will probably become the standard of care, although the clinicians should be aware of the overlapping toxicity of nucleoside analogues and ribavirin. Many selected categories of patients pose particular challenges to physicians treating HCV infection: nonresponders to interferon, cirrhotic patients, and patients infected with both HCV and HBV. Liver transplantation in HIV patients is currently under evaluation, but should become the rescue therapy for HIV patients with end stage liver disease. 相似文献
4.
5.
Maior JR Da Figueira MA Netto AB de Souza FB da Silva CH Tredwin CJ 《Operative dentistry》2007,32(3):261-265
This study evaluated the importance of the union between dentin collagen and three different adhesive materials. Sixty Class V restorations were prepared on the buccal and lingual surfaces of 30 recently extracted human premolars, with the cervical margins in dentin and the occlusal margins in enamel. These restorations were distributed to three groups of 20 cavities each based on the employed adhesive system used: Group A: Single Bond; Group B: Prime&Bond NT; Group C: One Coat Bond. Each group was subdivided according to dentin treatment: (1) manufacturers' adhesive protocol and (2) removal of the collagens fibers (total etch + sodium hypochlorite 5% for two minutes) + adhesive protocol. After the restorations were completed, the teeth were stored in saline solution (24 hours/37 degrees C), subjected to thermal cycling, washing and scoring according to dye penetration. Dye penetration was evaluated, with the numbers ranging from 0 (no infiltration) to 3 (greatest infiltration). When the dentin microleakage scores were compared in subgroups A1XA2, B1XB2 and C1XC2, the Mann-Whitney Test revealed significant differences between groups B and C (p < 5%). The better results were shown in subgroups B2 (p = 0.0345) and C2 (p = 0.0029). The results showed that the collagen fibrils were not necessary for adhesion, and their removal positively influenced the marginal sealing of Prime&Bond NT and One Coat Bond. 相似文献
6.
Stefan Wagenpfeil PhD María V Andrés PhD Vincente Belloch MD Teresa León MD PhD Teodoro del Ser MD for the TAUROS MRI Investigators 《Movement disorders》2014,29(4):479-487
It is believed that glycogen synthase kinase‐3 hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) trial assessed the glycogen synthase kinase‐3 inhibitor tideglusib as potential treatment. For the magnetic resonance imaging (MRI) substudy reported here, we assessed the progression of brain atrophy. TAUROS was a multinational, phase 2, double‐blind, placebo‐controlled trial in patients with mild‐to‐moderate PSP who were treated with oral tideglusib (600 mg or 800 mg daily) or with placebo for 1 year. A subset of patients underwent baseline and 52‐week MRI. Automated, observer‐independent, atlas‐based, and mask‐based volumetry was done on high‐resolution, T1‐weighted, three‐dimensional data. For primary outcomes, progression of atrophy was compared both globally (brain, cerebrum) and regionally (third ventricle, midbrain, pons) between the active and placebo groups (Bonferroni correction). For secondary outcomes, 15 additional brain structures were explored (Benjamini & Yekutieli correction). In total, MRIs from 37 patient were studied (placebo group, N = 9; tideglusib 600 mg group, N = 19; tideglusib 800 mg group, N = 9). The groups compared well in their demographic characteristics. Clinical results showed no effect of tideglusib over placebo. Progression of atrophy was significantly lower in the active group than in the placebo group for the brain (mean ± standard error of the mean: ?1.3% ± 1.4% vs. ?3.1% ± 2.3%, respectively), cerebrum (?1.3% ± 1.5% vs. ?3.2% ± 2.1%, respectively), parietal lobe (?1.6% ± 1.9% vs. ?4.1% ± 3.0%, respectively), and occipital lobe (?0.3% ± 1.8% vs. ?2.7% ± 3.2%, respectively). A trend toward reduced atrophy also was observed in the frontal lobe, hippocampus, caudate nucleus, midbrain, and brainstem. In patients with PSP, tideglusib reduced the progression of atrophy in the whole brain, particularly in the parietal and occipital lobes. © 2014 International Parkinson and Movement Disorder Society 相似文献
7.
Anthony W. Tolcher Razelle Kurzrock Vincente Valero Rene Gonzalez Rebecca S. Heist Antoinette R. Tan Julie Means-Powell Theresa L. Werner Carlos Becerra Chenxi Wang Cathrine Leonowens Shanker Kalyana-Sundaram Joseph F. Kleha Jennifer Gauvin Anthony M. DAmelio Catherine Ellis Nageatte Ibrahim Li Yan 《Cancer chemotherapy and pharmacology》2020,85(4):673-683
This study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEK and/or AKT inhibition. This was a phase I, open-label, dose-escalation, and dose-expansion study in patients with triple-negative breast cancer or BRAF-wild type advanced melanoma. The primary outcome of the expansion study was investigator-assessed response. Among 126 enrolled patients, 63 received continuous oral daily dosing of trametinib and uprosertib, 29 received various alternative dosing schedules, and 34 were enrolled into expansion cohorts. Doses tested in the expansion cohort were trametinib 1.5 mg once daily (QD) + uprosertib 50 mg QD. Adverse events (AEs) were consistent with those reported in monotherapy studies but occurred at lower doses and with greater severity. Diarrhea was the most common dose-limiting toxicity; diarrhea and rash were particularly difficult to tolerate. Overall, 59% and 6% of patients reported AEs with a maximum severity of grade 3 and 4, respectively. Poor tolerability prevented adequate delivery of uprosertib with trametinib at a concentration predicted to have clinical activity. The study was terminated early based on futility in the continuous-dosing expansion cohorts and a lack of pharmacological or therapeutic advantage with intermittent dosing. The objective response rate was < 5% (1 complete response, 5 partial responses). Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested. 相似文献
8.
Kaplan Carolyn R. Olive David L. Sabella Vincente Asch Ricardo H. Balmaceda Jose P. Riehl Robert M. Groff Terry R. Burns William N. Schenken Robert S. 《Journal of assisted reproduction and genetics》1989,6(5):298-304
Superovulation with intrauterine insemination (SO-IUI) has been suggested as an alternative to gamete intrafallopian transfer (GIFT), despite the absence of controlled or comparative trials. We retrospectively analyzed all GIFT and SO-IUI cycles performed concurrently from January 1985 to August of 1987 at a single university center. Pregnancy rates were significantly better for GIFT than SO-IUI (P<0.001), with an odds ratio of 3.25 (P=0.001). Stepwise multiple logistic regression identifield factors that correlate with pregnancy: absence of endometriosis (P=0.05), infertility<3 years' duration (P=0.002), TMS 30×106 (P=0.005), and treatment with GIFT rather than SO-IUI (P=0.001). These data give a first approximation of the increased efficacy of GIFT versus SO-IUI and provide valuable insight into significant confounding variables to be considered when planning a randomized, prospective trial to evaluate these techniques. 相似文献
9.
Chagpar A Middleton LP Sahin AA Meric-Bernstam F Kuerer HM Feig BW Ross MI Ames FC Singletary SE Buchholz TA Valero V Hunt KK 《Cancer》2005,103(8):1581-1586
BACKGROUND: The ideal pathologic assessment of sentinel lymph nodes (SLNs) in patients with breast carcinoma remains controversial. The authors evaluated how detailed assessment of SLNs using immunohistochemistry (IHC) and serial sectioning would affect treatment decisions and outcomes in patients with breast carcinoma who had negative SLNs on standard hematoxylin and eosin staining. METHODS: The SLNs from patients who were treated between June 1998 and June, 1999 and who had negative lymph node status determined by hematoxylin and eosin staining (n = 84 patients) were evaluated further with serial sectioning and cytokeratin IHC. Patients were offered adjuvant therapy based on primary tumor factors. RESULTS: The median patient age was 57 years, and the median tumor size was 1.2 cm. At a median follow-up of 40.2 months, 81 patients (96%) were alive with no evidence of disease, 1 patient was alive with disease, 1 patient had died of disease, and 1 patient had died of other causes. Fifteen patients (18%) had micrometastases identified on IHC. Of the total 84 patients, information regarding adjuvant therapy was not available for 5 patients. Of the remaining 79 patients, 10 patients (13%) were not offered adjuvant chemotherapy but had positive SLN status determined by IHC. SLN status based on IHC evaluation did not correlate with age (P = 0.077), tumor size (P = 0.717), grade (P = 0.148), estrogen receptor status (P = 1.000), or lymphovascular invasion (P = 0.274). Furthermore, IHC-detected positive SLN status did not correlate with distant metastasis (P = 0.372) or overall or distant metastasis-free survival (P = 0.543 and P = 0.540, respectively). CONCLUSIONS: Although the finding of SLN micrometastases by IHC may change management in > 12% of patients, preliminary results suggested that such micrometastases do not affect outcomes significantly. 相似文献